Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Downregulation of serum miR-30c-5p serves as a biomarker to predict disease onset and short-term prognosis in acute coronary syndrome patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101265113 Publication Model: Electronic Cited Medium: Internet ISSN: 1749-8090 (Electronic) Linking ISSN: 17498090 NLM ISO Abbreviation: J Cardiothorac Surg Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BioMed Central, 2006-
    • Subject Terms:
      Acute Coronary Syndrome*/blood ; Acute Coronary Syndrome*/diagnosis ; Acute Coronary Syndrome*/genetics ; MicroRNAs*/blood ; Down-Regulation* ; Biomarkers*/blood; Humans ; Female ; Male ; Prognosis ; Middle Aged ; Aged ; ROC Curve ; Predictive Value of Tests
    • Abstract:
      Competing Interests: Declarations. Ethics approval and consent to participate: The study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of The First People’s Hospital of Xiaoshan District before the study began. The informed consent has been obtained from the participants involved. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
      Background & Objective: Timely intervention for Acute coronary syndrome (ACS) could effectively reduce the mortality rate of ACS patients. This study aimed to investigate the clinical significance of miR-30c-5p for ACS and to provide a convenient biomarker for diagnosing of ACS.
      Methods: Baseline information was collected from a total of 173 subjects (98 ACS subjects and 65 healthy subjects). The miR-30c-5p expression was evaluated by the Polymerase chain reaction (PCR). The predictive value of miR-30c-5p for ACS was assessed by Receiver Operating Characteristic (ROC) curve and multivariate logistic regression analysis. The relationship between miR-30c-5p expression and ACS severity was assessed by correlation analysis. Furthermore, the prognostic value of miR-30c-5p on Major Adverse Cardiovascular Events (MACE) occurrence was assessed by the Kaplan-Meier (K-M) curve to evaluate its prognostic significance.
      Results: Downregulation of miR-30c-5p was observed in ACS subjects and its diagnostic value on ACS was confirmed by the ROC curve. MiR-30c-5p could also discriminate acute myocardial infarction (AMI) from unstable angina pectoris (UAP) subjects in ACS. The expression of miR-30c-5p was negatively correlated with the cardiac troponin I (cTnI) levels and the Gensini score. A lower miR-30c-5p expression was observed in ACS subjects who developed MACE (P = 0.020), and the K-M curve further confirmed the close correlation between miR-30c-5p expression and MACE occurrence in ACS. MiR-30c-5p was also identified as an independent prognostic factor for MACE in ACS.
      Conclusions: Serum miR-30c-5p expression was correlated with the severity of ACS, and downregulated miR-30c-5p expression showed a diagnostic and prognostic value in ACS.
      (© 2024. The Author(s).)
    • References:
      Open Med (Wars). 2022 Apr 06;17(1):676-688. (PMID: 35480402)
      Evid Based Complement Alternat Med. 2020 May 18;2020:3834128. (PMID: 32508947)
      Intern Emerg Med. 2017 Mar;12(2):147-155. (PMID: 28188579)
      Front Physiol. 2020 Jun 11;11:654. (PMID: 32595526)
      Biomarkers. 2017 Dec;22(8):701-708. (PMID: 28545334)
      Am Fam Physician. 2005 Jul 1;72(1):119-26. (PMID: 16035692)
      Circulation. 2023 Jan 17;147(3):e32-e62. (PMID: 36503287)
      JAMA. 2022 Feb 15;327(7):662-675. (PMID: 35166796)
      BMJ Open. 2021 Jul 7;11(7):e048994. (PMID: 34233996)
      Ther Clin Risk Manag. 2018 Nov 16;14:2255-2264. (PMID: 30532548)
      Cardiovasc Res. 2017 Nov 01;113(13):1627-1638. (PMID: 29016810)
      Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7. (PMID: 21037258)
      Rev Med Liege. 2018 May;73(5-6):243-250. (PMID: 29926562)
      J Am Coll Cardiol. 2017 Jul 4;70(1):1-25. (PMID: 28527533)
      Appl Biochem Biotechnol. 2024 Aug;196(8):5235-5248. (PMID: 38153649)
      Clin Lab. 2022 Feb 1;68(2):. (PMID: 35142189)
      Int J Environ Res Public Health. 2016 Sep 13;13(9):. (PMID: 27649220)
      Int J Mol Sci. 2018 May 15;19(5):. (PMID: 29762500)
      BMC Med Inform Decis Mak. 2019 Jan 9;19(1):5. (PMID: 30626381)
      Mol Med Rep. 2018 Aug;18(2):1311-1322. (PMID: 29845217)
      BMC Cardiovasc Disord. 2023 Jul 18;23(1):360. (PMID: 37464313)
      Life (Basel). 2023 Sep 29;13(10):. (PMID: 37895374)
      Biochem Biophys Res Commun. 2018 Sep 18;503(4):2833-2840. (PMID: 30119891)
      Cell. 2004 Jan 23;116(2):281-97. (PMID: 14744438)
      IUBMB Life. 2016 Aug;68(8):673-82. (PMID: 27346801)
      J Mol Cell Cardiol. 2021 Feb;151:155-162. (PMID: 32305360)
      Int J Mol Sci. 2022 Jun 06;23(11):. (PMID: 35683019)
      BMJ. 2015 Oct 20;351:h5153. (PMID: 26487159)
      J Clin Diagn Res. 2015 Oct;9(10):BC08-11. (PMID: 26557510)
      Arch Esp Urol. 2023 Aug;76(6):411-417. (PMID: 37681332)
    • Grant Information:
      B20210179 Hangzhou Medical and Health Science and Technology Project
    • Contributed Indexing:
      Keywords: ACS; MACE; Prognosis; Risk factor; miR-30c-5p
    • Accession Number:
      0 (MicroRNAs)
      0 (Biomarkers)
      0 (MIRN30a microRNA, human)
    • Publication Date:
      Date Created: 20250104 Date Completed: 20250106 Latest Revision: 20250107
    • Publication Date:
      20250114
    • Accession Number:
      PMC11699799
    • Accession Number:
      10.1186/s13019-024-03258-w
    • Accession Number:
      39755617